4th Quarter - Amendment

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$455,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 23, 2017 $315,000 Replaced
4th Quarter - Amendment (this page) Apr 20, 2017 $455,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to epinephrine auto-injectors pricing Prescription drug pricing, Generic Drugs HR 6, 21st Century Cures Act; Innovation for Healthier Americans Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, S. 3056 CREATES Act, H.R. 2841 FAST generics Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
MARCIE MCCLINTIC-COATES —
NIMISH SHAH —

Contacted: SENATE; Federal Trade Commission (FTC); Program Support Center; HOUSE OF REPRESENTATIVES

Bills named: S. 3056 (114th), H.R. 2841 (114th), H.R. 6 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.